Subjects: ANTIPSICÓTICOS (EFEITOS ADVERSOS), DENSIDADE ÓSSEA, OSSO E OSSOS, MORFOMETRIA
ABNT
MOTYL, Katherine J. et al. Trabecular bone loss after admistration of the second-generation antipsychotic risperidone is independent of weight gain. Bone, v. 50, n. 2, p. 490-498, 2012Tradução . . Disponível em: https://doi.org/10.1016/j.bone.2011.08.005. Acesso em: 20 abr. 2024.APA
Motyl, K. J., Dick-de-Paula, I., Maloney, A. E., Lotinum, S., Bornstein, S., Paula, F. J. A. de, et al. (2012). Trabecular bone loss after admistration of the second-generation antipsychotic risperidone is independent of weight gain. Bone, 50( 2), 490-498. doi:10.1016/j.bone.2011.08.005NLM
Motyl KJ, Dick-de-Paula I, Maloney AE, Lotinum S, Bornstein S, Paula FJA de, Baron R, Kouseknecht KL, Rosen CJ. Trabecular bone loss after admistration of the second-generation antipsychotic risperidone is independent of weight gain [Internet]. Bone. 2012 ; 50( 2): 490-498.[citado 2024 abr. 20 ] Available from: https://doi.org/10.1016/j.bone.2011.08.005Vancouver
Motyl KJ, Dick-de-Paula I, Maloney AE, Lotinum S, Bornstein S, Paula FJA de, Baron R, Kouseknecht KL, Rosen CJ. Trabecular bone loss after admistration of the second-generation antipsychotic risperidone is independent of weight gain [Internet]. Bone. 2012 ; 50( 2): 490-498.[citado 2024 abr. 20 ] Available from: https://doi.org/10.1016/j.bone.2011.08.005